Search: onr:"swepub:oai:gup.ub.gu.se/198756" >
Safety and tolerabi...
Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
-
Nitti, V W (author)
-
Chapple, C R (author)
-
Walters, C (author)
-
show more...
-
Blauwet, M B (author)
-
Herschorn, S (author)
-
- Milsom, Ian, 1950 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology
-
Auerbach, S (author)
-
Radziszewski, P (author)
-
show less...
-
(creator_code:org_t)
- 2014-04-06
- 2014
- English.
-
In: International journal of clinical practice. - : Hindawi Limited. - 1742-1241 .- 1368-5031. ; 68:8, s. 972-985
- Related links:
-
https://onlinelibrar...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- To evaluate the safety and tolerability of the β3 -adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database